K

Karma Clinical Trials | St. Johns, NL

Research site
(Unclaimed)
Location
63 Airport Road, St. John's, Newfoundland and Labrador, Canada

Site insights

Top conditions

Top treatments

Upadacitinib
Risankizumab
Apremilast
CC-10004
PF-04965842
Ixekizumab
JNJ-77242113
Guselkumab
Ruxolitinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 17 total trials

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue...

Active, not recruiting
Psoriasis
Drug: Apremilast

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Enrolling
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There...

Active, not recruiting
Psoriasis
Drug: Ustekinumab
Drug: Risankizumab

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Enrolling
Prurigo Nodularis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This...

Invitation-only
Psoriasis
Drug: Risankizumab

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Trial sponsors

AbbVie logo
AbbVie logo
Amgen logo
Incyte logo
Janssen (J&J Innovative Medicine) logo
Lilly logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems